Gastric Cancer Registry Prepares to Launch Innovative Data Portal
The Gastric Cancer Registry is the first comprehensive repository of clinical and genomic data pertaining to stomach cancer. Its chief aims are... Read More
Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer
Five Prime Therapeutics’ FGFR2b-targeted drug combined with chemotherapy improved survival in a phase 2 trial.
Immunotherapy May Work Better Against Stomach Cancer When Combined with Chemo, Given Earlier
Columbia University Researchers showed in a preclinical study that combining immunotherapy with chemotherapy in the early stages of gastric cancer slowed down... Read More
Gritstone Oncology Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE
Gritstone Oncology has expanded a phase 2 clinical trial of its personalized cell therapy to include patients with gastric cancer.
FDA Grants Orphan Drug Designation to Investigational CAR T-Cell Agent in Gastric/GEJ Cancer
The FDA granted Orphan Drug designation to CARsgen Therapeutics for a CAR T-cell treatment it’s developing to treat gastric cancer.
Singapore Clinicians and Scientists Achieve Big Leap in Early Diagnosis of Gastric Cancer Through the Development of Non-Invasive Blood-based Test
Researchers in Singapore have developed a blood test that they believe could be used for early detection of gastric cancer.
UArizona Health Sciences Researchers Find Biomarker that Can Appear Before Stomach Cancer Develops
Researchers at the University of Arizona discovered a biomarker that appears in people before stomach cancer develops and that can be detected... Read More
Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics
In a trial combining Keytruda with Oncologie’s investigational drug that targets phosphatidylserine, the response rate was 43% among patients with a low... Read More
Foundation-Funded Lab at MD Anderson Advances Discoveries in Peritoneal Carcinomatosis
About 45% of gastric cancer patients experience peritoneal carcinomatosis (PC), the spread of the cancer to the abdominal lining—a development that’s associated... Read More
Frontline Nivolumab/Chemo Combo Improves Survival in Gastric/GEJ Cancer and Esophageal Adenocarcinoma
Bristol Myers Squibb’s Opdivo improved survival in previously untreated gastric cancer patients in a trial presented at ESMO20.